Literature DB >> 10975876

Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development.

M Basille1, D Vaudry, Y Coulouarn, S Jegou, I Lihrmann, A Fournier, H Vaudry, B Gonzalez.   

Abstract

The distribution and density of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites as well as PACAP-specific receptor 1 (PAC1-R), vasoactive intestinal polypeptide/PACAP receptor 1 (VPAC1-R), and VPAC2-R mRNAs have been investigated in the rat brain from embryonic day 14 (E14) to postnatal day 8 (P8). Significant numbers of binding sites for the radioiodinated, 27-amino-acid form of PACAP were detected as early as E14 in the neuroepithelia of the metencephalon and the myelencephalon. From E14 to E21, the density of binding sites in the germinative areas increased by 3- to 5-fold. From birth to P12, the density of binding sites gradually declined in all neuroepithelia except in the external granule cell layer of the cerebellum, where the level of binding sites remained high during the first postnatal weeks. Only low to moderate densities of PACAP binding sites were found in regions other than the germinative areas, with the exception of the internal granule cell layer of the cerebellum, which contained a high density of sites. The localization of PACAP receptor mRNAs was investigated by in situ hybridization using [(35)S] uridine triphosphate-specific riboprobes. The evolution of the distribution of PAC1-R and VPAC1-R mRNAs was very similar to that of PACAP binding sites, the concentration of VPAC1-R mRNA being much lower than that of PAC1-R mRNA. In contrast, intense expression of VPAC2-R mRNA was observed in brain regions other than germinative areas, such as the suprachiasmatic, ventral thalamic, and dorsolateral geniculate nuclei. The discrete localization of PACAP binding sites as well as PAC1-R and VPAC1-R mRNAs in neuroepithelia during embryonic life and postnatal development strongly suggests that PACAP, acting through PAC1-R and/or VPAC1-R, may play a crucial role in the regulation of neurogenesis in the rat brain. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975876

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  27 in total

Review 1.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Granule cell survival is deficient in PAC1-/- mutant cerebellum.

Authors:  Anthony Falluel-Morel; Liana I Tascau; Katie Sokolowski; Philippe Brabet; Emanuel DiCicco-Bloom
Journal:  J Mol Neurosci       Date:  2008-04-12       Impact factor: 3.444

3.  VIP blockade leads to microcephaly in mice via disruption of Mcph1-Chk1 signaling.

Authors:  Sandrine Passemard; Vincent El Ghouzzi; Hala Nasser; Catherine Verney; Guilan Vodjdani; Adrien Lacaud; Sophie Lebon; Marc Laburthe; Patrick Robberecht; Jeannette Nardelli; Shyamala Mani; Alain Verloes; Pierre Gressens; Vincent Lelièvre
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

4.  PACAP Protects the Adolescent and Adult Mice Brain from Ethanol Toxicity and Modulates Distinct Sets of Genes Regulating Similar Networks.

Authors:  Hélène Lacaille; Dominique Duterte-Boucher; Hubert Vaudry; Yasmine Zerdoumi; Jean-Michel Flaman; Hitoshi Hashimoto; David Vaudry
Journal:  Mol Neurobiol       Date:  2016-11-08       Impact factor: 5.590

5.  Pituitary adenylate cyclase-activating polypeptide induces postsynaptically expressed potentiation in the intra-amygdala circuit.

Authors:  Jun-Hyeong Cho; Ko Zushida; Gleb P Shumyatsky; William A Carlezon; Edward G Meloni; Vadim Y Bolshakov
Journal:  J Neurosci       Date:  2012-10-10       Impact factor: 6.167

6.  Cycloheximide treatment to identify components of the transitional transcriptome in PACAP-induced PC12 cell differentiation.

Authors:  Aurélia Ravni; Lee E Eiden; Hubert Vaudry; Bruno J Gonzalez; David Vaudry
Journal:  J Neurochem       Date:  2006-06-19       Impact factor: 5.372

Review 7.  Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.

Authors:  Anne Luise Haulund Vollesen; Faisal Mohammad Amin; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

8.  Pro- and anti-mitogenic actions of pituitary adenylate cyclase-activating polypeptide in developing cerebral cortex: potential mediation by developmental switch of PAC1 receptor mRNA isoforms.

Authors:  Yan Yan; Xiaofeng Zhou; Zui Pan; Jianjie Ma; James A Waschek; Emanuel DiCicco-Bloom
Journal:  J Neurosci       Date:  2013-02-27       Impact factor: 6.167

Review 9.  Interactions of PACAP and ceramides in the control of granule cell apoptosis during cerebellar development.

Authors:  A Falluel-Morel; N Aubert; D Vaudry; A Desfeux; A Allais; D Burel; M Basille; H Vaudry; V Laudenbach; B J Gonzalez
Journal:  J Mol Neurosci       Date:  2008-06-24       Impact factor: 3.444

Review 10.  Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.

Authors:  Satomi Onoue; Shingen Misaka; Shizuo Yamada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.